10x Genomics (NASDAQ:TXG) Given New $60.00 Price Target at Citigroup

10x Genomics (NASDAQ:TXG) had its price objective boosted by Citigroup from $50.00 to $60.00 in a research note published on Friday morning,Benzinga reports. They currently have a neutral rating on the stock.

A number of other research firms have also recently commented on TXG. TD Cowen lifted their price target on shares of 10x Genomics from $47.00 to $70.00 and gave the stock a “hold” rating in a report on Tuesday, October 13th. Morgan Stanley increased their price objective on 10x Genomics from $40.00 to $70.00 and gave the company an “equal weight” rating in a report on Monday, October 12th. Barclays raised their target price on 10x Genomics from $52.00 to $110.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 7th. UBS Group lowered their target price on 10x Genomics from $90.00 to $61.00 and set a “neutral” rating on the stock in a research note on Friday. Finally, Argus started coverage on 10x Genomics in a research note on Monday, September 28th. They issued a “buy” rating and a $110.00 target price on the stock. Five analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $68.07.

10x Genomics Price Performance

Shares of 10x Genomics stock traded up $1.22 during trading hours on Friday, hitting $59.28. 4,522,645 shares of the company’s stock traded hands, compared to its average volume of 4,178,377. 10x Genomics has a 12-month low of $13.58 and a 12-month high of $102.81. The stock has a market capitalization of $7.72 billion, a price-to-earnings ratio of -114.00 and a beta of 2.03. The company has a fifty day simple moving average of $73.95 and a 200-day simple moving average of $41.59.

10x Genomics (NASDAQ:TXG) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.12. The company had revenue of $150.67 million for the quarter, compared to the consensus estimate of $147.96 million. 10x Genomics had a negative net margin of 12.18% and a negative return on equity of 9.33%. The firm’s quarterly revenue was up 1.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.22) EPS. On average, analysts forecast that 10x Genomics will post -0.77 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Adam Taich sold 46,388 shares of the company’s stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $64.57, for a total transaction of $2,995,273.16. Following the sale, the chief financial officer directly owned 316,344 shares in the company, valued at approximately $20,426,332.08. This represents a 12.79% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Serge Saxonov sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $81.22, for a total transaction of $2,030,500.00. Following the completion of the transaction, the chief executive officer directly owned 1,050,249 shares of the company’s stock, valued at approximately $85,301,223.78. This trade represents a 2.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 179,333 shares of company stock valued at $11,810,070. Corporate insiders own 8.84% of the company’s stock.

Institutional Investors Weigh In On 10x Genomics

Several institutional investors have recently made changes to their positions in the stock. Werba Rubin Papier Wealth Management bought a new position in shares of 10x Genomics in the third quarter worth $347,000. Lido Advisors LLC bought a new stake in shares of 10x Genomics during the 3rd quarter valued at $256,000. AlphaCore Capital LLC purchased a new stake in 10x Genomics during the 3rd quarter worth about $200,000. Fulcrum Asset Management LLP bought a new position in 10x Genomics in the 3rd quarter worth about $8,793,000. Finally, Allspring Global Investments Holdings LLC grew its holdings in 10x Genomics by 3.4% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 16,229 shares of the company’s stock valued at $1,440,000 after buying an additional 539 shares in the last quarter. Hedge funds and other institutional investors own 84.68% of the company’s stock.

Key 10x Genomics News

Here are the key news stories impacting 10x Genomics this week:

• Positive Sentiment: 10x Genomics reported a Q3 loss of $0.15 per share, narrower than analysts’ expectations, while revenue of $150.7 million topped estimates. The company also raised its 2026 revenue outlook to $625 million–$635 million, above the roughly $620 million consensus. Q3 results
• Positive Sentiment: The company launched Sentira Single Cell, an AI-powered tool intended to simplify cell-data analysis. The product could support research adoption and create recurring revenue opportunities. Sentira launch
• Neutral Sentiment: Citigroup raised its price target from $50 to $60 but kept a neutral rating, suggesting limited upside at the cited share price. Citi target update
• Negative Sentiment: UBS cut its target from $90 to $61 and maintained a neutral rating. Meanwhile, Q3 revenue grew just 1.1% year over year and the company remains loss-making; management also cited production constraints and margin pressure, tempering optimism around stronger Atera demand. UBS target update Q3 call highlights

About 10x Genomics

10x Genomics, Inc is a life sciences technology company that develops tools for analyzing biological systems at the single-cell and spatial levels. Its technologies are designed to help researchers study gene expression, cellular interactions, tissue organization and other biological processes in greater detail than conventional laboratory methods.

The company’s product portfolio includes the Chromium platform for single-cell analysis, the Visium platform for spatial transcriptomics, and the Xenium platform for high-resolution in situ analysis of tissue samples.